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Increased intestinal permeability in ankylosing spondylitis SIR,-We read with great interest the excellent paper by Morris et al (Gut 1991; 32: 1470-2) on intestinal permeability in ankylosing spondylitis but we do not agree, however, with their conclusions.
Using the "Cr-EDTA resorption test'2 we recently studied gut permeability in inflammatory rheumatic disorders. Intake of nonsteroidal anti-inflammatory drugs (NSAIDs) significantly increases gut permeability irrespective of the underlying disease. Patients with ankylosing spondylitis and with other spondylarthropathies not taking NSAIDs also presented a significant increase of gut permeability compared with controls. This indicates that the disturbance is disease related.
Gut permeability was not significantly increased in patients with histological gut lesions on ileocolonoscopy, or in patients with a normal ileum, although patients with ankylosing spondylitis and chronic gut lesions (resembling Crohn's disease) showed a significant increase in gut permeability compared with patients with ankylosing spondylitis and acute gut lesions.
There are several explanations for the absence of a relationship between increased gut permeability and ileocolonoscopic evidence of gut inflammation. On ileocolonoscopy only the terminal aspect of the ileum, which is only a very small part of the small bowel, can be examined. Moreover, the distribution of the observed lesions was patchy. Intake of NSAIDs causes such major disturbances in gut permeability that minor and local inflammation of the ileum would not influence the results of the "Cr-EDTA resorption test.
Inflammatory gut lesions were not found in patients with rheumatoid arthritis3 taking high doses of NSAIDs for prolonged periods, while such lesions were present in more than 50 patients with spondyloarthropathies4 who had not taken antiinflammatory drugs. This suggests that primary lesion in the ileocaecal region is associated with the spondyloarthropathies, while intake of NSAIDs probably induces more extensive and diffuse functional disturbances of the entire small bowel. (Gut 1991; 32: 1303-7) for evaluating their postgastrectomy patients for metabolic bone disease. All too often, we, as physicians caring for patients with gastrointestinal problems that lead to abnormal bone nutrition and metabolism -that is, postgastrectomy, inflammatory bowel disease, small bowel malabsorption, and states of diminished oral intake, ignore the patients' developing bone disease because the process is insidious and the patients are often asymptomatic until the disease is so profound that much of it may be irreversible.
I must take issue, however, with the authors' conclusion advocating supplemental vitamin D for all postgastrectomy patients. The authors have found evidence of bone abnormalities by histomorphometry in up to 62% of 51 patients, but only eight patients were considered to have osteomalacia. It is not clear that vitamin D supplementation is beneficial in nonosteomalacia bone disorders.
The authors suggest that the low mean levels of 25-hydroxyvitamin D are relevant and thus warrant supplementation. Yet, five of eight patients with a diagnosis of osteomalacia had normal levels, highlighting the lack of value serum measurements may have in predicting bone disorder diagnoses. The authors do not state how many of their non-osteomalacia patients had levels that were abnormal (they state only that the mean overall was abnormal). 
